HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target

Benzinga ·  11/06/2023 20:05

HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment